核医学诊疗一体化在分化型甲状腺癌术后评估中的应用OACSTPCD
Nuclear medicine theranostics for the management of differentiated thyroid carcinoma
分化型甲状腺癌(DTC)因其发病率逐年增高而引人关注,伴随着核医学诊疗一体化手段的不断完善以及分子生物学等技术在DTC中的深入研究,有关其诊断及治疗理念也在不断更新.本文结合现有的诊疗一体化实践以及循证医学证据和相关指南推荐,对131I治疗前评估体系进行系统阐述.
With the increase of its incidence,differentiated thyroid carcinoma(DTC)has become a global concern.Over the recent decades,the guidelines for the management of DTC have been kept updating along with the development of nuclear medicine theranostics and molecular biology.The present article will systematically expound on the 131I pre-treatment evaluation system based on the clinical practice of nuclear medicine theranostics,the latest evidence-based medical evidence,and guideline recommendations.
张英杰;林岩松
山东第一医科大学附属肿瘤医院核医学科(山东省肿瘤防治研究院,山东省肿瘤医院),山东济南 250071中国医学科学院、北京协和医学院北京协和医院核医学科,北京 100730
临床医学
甲状腺肿瘤核医学诊疗一体化
thyroid neoplasmnuclear medicinetheranostics
《西安交通大学学报（医学版）》 2024 (001)
循环肿瘤特征在碘难治性分化型甲状腺癌早期预测、诊断及疗效评估体系中的意义
15-22 / 8
国家重点研发计划"政府间国际科技创新合作/港澳台科技创新合作"重点专项(No.2019YFE0106400);中央高水平医院临床科研业务费资助(No.2022-PUMCH-B-072);国家自然科学基金项目(No.81771875);山东省自然科学基金项目(No.ZR2019PH051)Supported by Project on Inter-Governmental International Scientific and Technological Innovation Cooperation in National Key Projects of Research and Development Plan(No.2019YFE0106400),National High Level Hospital Clinical Research Funding(No.2022-PUMCH-B-072),the National Natural Science Foundation of China(No.81771875)and Shandong Provincial Natural Science Founda-tion(No.ZR2019PH051)
评论